A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Part of paid clinical trials in Chicago, Illinois.

Sponsor
UCB Biopharma SRL
Study ID
NCT06055959
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Generalized Myasthenia Gravis

Eligibility Criteria

Sex
ALL
Age
12 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Zilucoplan — DRUG
    Zilucoplan will be administered subcutaneously to pediatric study participants.

Study Details

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

Key Dates

Start date
Oct 16, 2024
Status verified
May 2026
Primary completion
Nov 16, 2026
Completion
Dec 25, 2026

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zilucoplan Arm
    Study participants will receive zilucoplan in pre-defined dose based on their weight.

Primary Outcome Measure

Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29) [ Time Frame: Week 4 (Day 29) ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mg0014 50168ChicagoIllinois60611-
Mg0014 50574DentonTexas76208-

Find similar trials in Chicago, IL

By research site
Mg0014 50168· Chicago, ILMg0014 50574· Denton, TX

Related Studies